Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

被引：6

作者：

Benza, Raymond L. ^{[1
]}

Langleben, David ^{[2
]}

Hemnes, Anna R. ^{[3
]}

Noordegraaf, Anton Vonk ^{[4
]}

Rosenkranz, Stephan ^{[5
]}

Thenappan, Thenappan ^{[6
]}

Hassoun, Paul M. ^{[7
]}

Preston, Ioana R. ^{[8
]}

Ghio, Stefano ^{[9
]}

Badagliacca, Roberto ^{[10
]}

Vizza, Carmine D. ^{[10
]}

Lang, Irene M. ^{[11
]}

Meier, Christian ^{[12
]}

Gruenig, Ekkehard ^{[13
]}

机构：

[1] Ohio State Univ Wexner Med Ctr, Dept Med, Columbus, OH 43210 USA

[2] McGill Univ, Jewish Gen Hosp, Ctr Pulm Vasc Dis, Div Cardiol, Montreal, PQ, Canada

[3] Vanderbilt Univ Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA

[4] Vrije Univ Amsterdam Med Ctr, Pulm Dis, Amsterdam, Netherlands

[5] Cologne Univ Heart Ctr, Dept Cardiol, Cologne, Germany

[6] Univ Minnesota, Dept Med, Cardiovasc Div, Minneapolis, MN USA

[7] Johns Hopkins Univ, Pulm & Crit Care Med, Baltimore, MD USA

[8] Tufts Med Ctr, Pulm Crit Care & Sleep Med Div, Boston, MA USA

[9] Fdn IRCCS Policlin San Matteo, Div Cardiol, Pavia, Italy

[10] Sapienza Univ, Dept Cardiol, Rome, Italy

[11] Med Univ Vienna, Allgemeines Krankenhaus, Dept Internal Medicine 2, Div Cardiol, Vienna, Austria

[12] Global Med Affairs, Bayer AG, Berlin, Germany

[13] Heidelberg Univ Hosp, Ctr Pulm Hypertens, Thoraxklin Heidelberg gGmbH, Heidelberg, Germany

来源：

EUROPEAN RESPIRATORY REVIEW | 2022年 / 31卷 / 166期

关键词：

SOLUBLE GUANYLATE-CYCLASE; ENDOTHELIN-RECEPTOR ANTAGONIST; RIGHT HEART; EXERCISE CAPACITY; BOSENTAN TREATMENT; PROGNOSTIC VALUE; SILDENAFIL; PARAMETERS; MANAGEMENT; SURVIVAL;

D O I：

10.1183/16000617.0061-2022

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH.

引用

页数：12

共 50 条

[1] Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Bishop, Bryan M.
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (21) : 1839 - 1844
[2] RIOCIGUAT FOR THE MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION AND CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Larche, N. E.
Mousa, S. A.
[J]. DRUGS OF TODAY, 2013, 49 (12) : 761 - 768
[3] Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Benza, Raymond L.
Ghofrani, Hossein-Ardeschir
Grunig, Ekkehard
Hoeper, M. Marius
Jansa, Pavel
Jing, Zhi-Cheng
Kim, Nick H.
Langleben, David
Simonneau, Gerald
Wang, Chen
Busse, Dennis
Meier, Christian
Ghio, Stefano
[J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (10): : 1172 - 1180
[4] Riociguat: A Novel Therapeutic Option for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Mielniczuk, Lisa M.
Swiston, John R.
Mehta, Sanjay
[J]. CANADIAN JOURNAL OF CARDIOLOGY, 2014, 30 (10) : 1233 - 1240
[5] Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Kambakamba, Adrian
Tello, Khodr
Axmann, Jens
Gall, Henning
Ghofrani, Ardeschir
Guth, Stefan
Wiedenroth, Christoph
Richter, Manuel Jonas
[J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
[6] Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
Ghofrani, H. A.
Hoeper, M. M.
Halank, M.
Meyer, F. J.
Staehler, G.
Behr, J.
Ewert, R.
Weimann, G.
Grimminger, F.
[J]. EUROPEAN RESPIRATORY JOURNAL, 2010, 36 (04) : 792 - 799
[7] Rapid Titration of Riociguat in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Katta, S.
Safdar, Z.
Sahay, S.
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[8] Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
Marra, Alberto M.
Halank, Michael
Benjamin, Nicola
Bossone, Eduardo
Cittadini, Antonio
Eichstaedt, Christina A.
Egenlauf, Benjamin
Harutyunova, Satenik
Fischer, Christine
Gall, Henning
Ghofrani, Hossein Ardeschir
Hoeper, Marius M.
Lange, Tobias J.
Olsson, Karen M.
Klose, Hans
Gruenig, Ekkehard
[J]. RESPIRATORY RESEARCH, 2018, 19
[9] Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
Alberto M. Marra
Michael Halank
Nicola Benjamin
Eduardo Bossone
Antonio Cittadini
Christina A. Eichstaedt
Benjamin Egenlauf
Satenik Harutyunova
Christine Fischer
Henning Gall
Hossein Ardeschir Ghofrani
Marius M. Hoeper
Tobias J. Lange
Karen M. Olsson
Hans Klose
Ekkehard Grünig
[J]. Respiratory Research, 19
[10] Effects on Right Ventricular size and function by Riociguat in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension (The RIVER Study)
Marra, A. M.
Benjamin, N.
Eichstaedt, C.
Egenlauf, B.
Fischer, C.
Gall, H.
Ghofrani, H. A.
Halank, M.
Hoeper, M. M.
Lange, T.
Olsson, K.
Gruenig, E.
[J]. EUROPEAN HEART JOURNAL, 2018, 39 : 633 - 633

← 1 2 3 4 5 →